Gilead’s BIXLENVO is the the most recent FDA-approved HIV medication available to patients who already have their HIV under control, but who remain on complicated or multi-pill treatment regimens. The BIXLENVO tablet combines bictegravir, the backbone of Gilead’s blockbuster HIV pill BIKTARVY, with lenacapavir, a centerpiece of the company’s long-term strategy for HIV treatment and prevention. After the completion of a two-day starter dose, patients need only take BIXLENVO once daily for disease markers to remain undetectable.

As a senior member of the team, I was deeply involved in the planning and execution of the BIXLENVO Now Approved campaign from the very beginning of the project all the way through launch day. Major assigned responsibilities included conceptual exploration of the campaign look/feel, oversight over two freelancers brought on to aid with the launch, and primary ownership and development the BIXLENVO website in Figma.